MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Gilead Sciences Inc.

Atidarymo kaina

SektoriusSveikatos priežiūra

103.26 -3.62

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

100.88

Max

107.3

Pagrindiniai rodikliai

By Trading Economics

Pajamos

530M

1.8B

Pardavimai

29M

7.6B

P/E

Sektoriaus vid.

274.553

57.333

Pelnas, tenkantis vienai akcijai

1.9

Dividendų pajamingumas

3.02

Pelno marža

23.557

Darbuotojai

17,600

EBITDA

-655M

3.1B

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+9.79% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

3.02%

2.63%

Kitas dividendų mokėjimo data

2025-06-26

Kita Ex Dividend data

2025-06-13

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

8.7B

130B

Ankstesnė atidarymo kaina

106.88

Ankstesnė uždarymo kaina

103.26

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

Gilead Sciences Inc. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-04-24 20:17; UTC

Uždarbis

Gilead Sciences Swings to 1Q Profit, But Slashes FY25 EPS Guidance

2025-02-11 21:17; UTC

Uždarbis

Gilead Sciences 4Q Profit Up on HIV Product Sales, Dividend Raised

2025-04-24 20:08; UTC

Uždarbis

Gilead Sciences Earnings Were Solid. How the S&P 500's No. 1 Health Stock Did. -- Barrons.com

2025-04-24 20:02; UTC

Uždarbis

Gilead Sciences Sees 2025 Adj EPS $7.70-Adj EPS $8.10 >GILD

2025-04-24 20:02; UTC

Uždarbis

Gilead Sciences: As of March 31, 2025, $7.9 Billion of Cash and Cash Equivalents Compared to $10.0 Billion as of Dec. 31, 2024 >GILD

2025-04-24 20:02; UTC

Uždarbis

Gilead Sciences 1Q Rev $6.67B >GILD

2025-04-24 20:02; UTC

Uždarbis

Gilead Sciences: 1Q Product Gross Margin Was 76.7% Compared to 76.6% in Same Period in 2024 >GILD

2025-04-24 20:02; UTC

Uždarbis

Gilead Sciences: During 1Q Generated $1.8 Billion in Operating Cash Flow >GILD

2025-04-24 20:02; UTC

Uždarbis

Gilead Sciences 1Q Adj EPS $1.81 >GILD

2025-04-24 20:02; UTC

Uždarbis

Gilead Sciences: 1Q Lower Veklury (Remdesivir) and Oncology Sales Offset by Higher HIV and Liver Disease Sales >GILD

2025-04-24 20:02; UTC

Uždarbis

Gilead Sciences Sees 2025 EPS $5.65-EPS $6.05 >GILD

2025-04-24 20:02; UTC

Uždarbis

Gilead Sciences 1Q EPS $1.04 >GILD

2025-04-24 20:02; UTC

Uždarbis

Gilead Sciences 1Q EPS $1.04 >GILD

2025-04-24 20:02; UTC

Uždarbis

Gilead Sciences Sees FY EPS $5.65-EPS $6.05 >GILD

2025-04-24 20:02; UTC

Uždarbis

Gilead Sciences 1Q Total Liver Disease Sales $758M >GILD

2025-04-24 20:02; UTC

Uždarbis

Gilead Sciences 1Q Net $1.32B >GILD

2025-04-24 20:02; UTC

Uždarbis

Gilead Sciences 1Q Adj EPS $1.81 >GILD

2025-04-24 20:02; UTC

Uždarbis

Gilead Sciences Sees FY Adj EPS $7.70-Adj EPS $8.10 >GILD

2025-04-24 20:02; UTC

Uždarbis

Gilead Sciences 1Q Rev $6.7B >GILD

2025-04-11 09:30; UTC

Svarbiausios naujienos

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

2025-03-19 14:50; UTC

Svarbiausios naujienos

HIV Drug Makers Get Spooked by Trump Cuts, but Impact Looks Manageable -- Heard on the Street -- WSJ

2025-02-28 12:00; UTC

Svarbiausios naujienos

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

2025-02-11 22:13; UTC

Rinkos pokalbiai
Uždarbis

Gilead's HIV Segment Buoying Product Sales Amid Covid Losses -- Market Talk

2025-02-11 21:06; UTC

Uždarbis

Gilead Beats Earnings Estimates on Strong HIV Sales -- Barrons.com

2025-02-11 21:02; UTC

Uždarbis

Gilead Sciences Planning for Potential Launch of Lenacapavir for HIV PrEP in Summer 2025>GILD

2025-02-11 21:02; UTC

Uždarbis

Gilead Sciences Sees 2025 EPS $5.95-EPS $6.35 >GILD

2025-02-11 21:02; UTC

Uždarbis

Gilead Sciences Raises Dividend to 79c Vs. 77c >GILD

2025-02-11 21:02; UTC

Uždarbis

Gilead Sciences Sees 2025 Product Sales Excluding Veklury $26.8B - $27.2B>GILD

2025-02-11 21:02; UTC

Uždarbis

Gilead Sciences Raises Dividend 2.6%>GILD

2025-02-11 21:02; UTC

Uždarbis

Gilead Sciences Sees 2025 Adj EPS $7.70-Adj EPS $8.10 >GILD

Akcijų palyginimas

Kainos pokytis

Gilead Sciences Inc. Prognozė

Kainos tikslas

By TipRanks

9.79% į viršų

12 mėnesių prognozė

Vidutinis 116.79 USD  9.79%

Aukščiausias 140 USD

Žemiausias 89 USD

Remiantis 24 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Gilead Sciences Inc. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

24 ratings

18

Pirkti

6

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

105 / 106.5Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Very Strong Bearish Evidence

Ilgalaikis periodas

Weak Bullish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.